A case of fulminant hepatic failure due to cyproterone acetate in a patient with cryptogenic liver cirrhosis.
- Author:
Byoung Ho KIM
1
;
Dong Joon KIM
;
Kyoung Min SOHN
;
Ha Na YANG
;
Myung Jin CHOI
;
Chan Woo LEE
;
Kyung Chan CHOI
Author Information
1. Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea. djkim@hallym.ac.kr
- Publication Type:Case Report
- Keywords:
Cyproterone acetate;
Liver failure;
Prostatic neoplasms;
Hepatitis, Toxic
- MeSH:
Biopsy;
Cyproterone;
Cyproterone Acetate;
Drug-Induced Liver Injury;
Fibrosis;
Hepatitis;
Humans;
Liver;
Liver Cirrhosis;
Liver Diseases;
Liver Failure;
Liver Failure, Acute;
Prostatic Neoplasms
- From:Korean Journal of Medicine
2009;77(Suppl 1):S31-S35
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cyproterone acetate is an antiandrogenic drug that has been used in prostatic cancer. The drug is thought to be well-tolerated but has hepatotoxic effects. An 89 year-old man treated with cyproterone acetate 300 mg/d for prostatic cancer presented with a hepatotoxic reaction. Toxic hepatitis was diagnosed and cyproterone acetate was stopped immediately. The patient was treated with supportive management and a corticosteroid, but he died 28 days after administration due to liver failure. A liver biopsy performed after his death revealed the presence of acute hepatitis with cirrhosis. Underlying cirrhosis was not suspected before his death. Ultimately, the case was diagnosed as fulminant hepatic failure due to cyproterone acetate with underlying cryptogenic liver cirrhosis. This case and current literature highlight the hepatotoxic potential of cyproterone acetate and illustrate the importance of clinical surveillance, especially in patients with unrecognized liver disease.
